Off-label use of targeted therapies in oncology

被引：22
作者：
Leveque, Dominique [1 ]
机构：
[1] Hop Hautepierre, Div Pharm, Ave Moliere, F-67000 Strasbourg, France
来源：
WORLD JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 7卷 / 02期
关键词：
Targeted therapy; Monoclonal antibody; Off-label anticancer drug use; Reimbursement; Enzyme inhibitor;
D O I：
10.5306/wjco.v7.i2.253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Off-label use is defined by the prescription of a marketed drug outside the conditions described in the summary of product characteristics. In oncology, off-label prescribing of targeted therapies may occur in patients with other tumor types expressing the same target. Agents associated to phenotypic approaches such as therapies against the tumoral vasculature (anti-angiogenic drugs) and new immunotherapies (checkpoint inhibitors) also carry the potential of alternative indications or combinations. Off-label use of targeted therapies is little documented and appears to be in the same range than that regarding older drugs with wide variations among agents. When compared with older agents, off-label use of targeted therapies is probably more rational through tumoral genotyping but is faced with a limited clinical support, reimbursement challenges related to the very high pricing and the cost of genotyping or molecular profiling, when applicable.
引用
收藏
页码：253 / 257
页数：5
相关论文
共 29 条
  • [1] Bevacizumab in Clinical Practice: Prescribing Appropriateness Relative to National Indications and Safety
    Bonifazi, Martina
    Rossi, Marta
    Moja, Lorenzo
    Scigliano, Vincenzo Davide
    Franchi, Matteo
    La Vecchia, Carlo
    Zocchetti, Carlo
    Negri, Eva
    [J]. ONCOLOGIST, 2012, 17 (01) : 117 - 124
  • [2] Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
    Brose, Marcia S.
    Nutting, Christopher M.
    Jarzab, Barbara
    Elisei, Rossella
    Siena, Salvatore
    Bastholt, Lars
    de la Fouchardiere, Christelle
    Pacini, Furio
    Paschke, Ralf
    Shong, Young Kee
    Sherman, Steven I.
    Smit, Johannes W. A.
    Chung, John
    Kappeler, Christian
    Pena, Carol
    Molnar, Istvan
    Schlumberger, Martin J.
    [J]. LANCET, 2014, 384 (9940) : 319 - 328
  • [3] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
    Conroy, Thierry
    Desseigne, Francoise
    Ychou, Marc
    Bouche, Olivier
    Guimbaud, Rosine
    Becouarn, Yves
    Adenis, Antoine
    Raoul, Jean-Luc
    Gourgou-Bourgade, Sophie
    de la Fouchardiere, Christelle
    Bennouna, Jaafar
    Bachet, Jean-Baptiste
    Khemissa-Akouz, Faiza
    Pere-Verge, Denis
    Delbaldo, Catherine
    Assenat, Eric
    Chauffert, Bruno
    Michel, Pierre
    Montoto-Grillot, Christine
    Ducreux, Michel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) : 1817 - 1825
  • [4] Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists
    Conti, Rena M.
    Bernstein, Arielle C.
    Villaflor, Victoria M.
    Schilsky, Richard L.
    Rosenthal, Meredith B.
    Bach, Peter B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (09) : 1134 - 1139
  • [5] Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E -Positive Papillary Thyroid Cancer: MD Anderson Cancer Center Off Label Experience
    Dadu, Ramona
    Shah, Komal
    Busaidy, Naifa L.
    Waguespack, Steven G.
    Habra, Mouhammad A.
    Ying, Anita K.
    Hu, Mimi I.
    Bassett, Roland
    Jimenez, Camilo
    Sherman, Steven I.
    Cabanillas, Maria E.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (01) : E77 - E81
  • [6] Outcomes of off-label drug uses in hospitals: a multicentric prospective study
    Danes, I.
    Agusti, A.
    Vallano, A.
    Alerany, C.
    Martinez, J.
    Bosch, J. A.
    Ferrer, A.
    Gratacos, L.
    Perez, A.
    Olmo, M.
    Cano Marron, S. M.
    Valderrama, A.
    Bonafont, X.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (11) : 1385 - 1393
  • [7] Comprehensive analysis of kinase inhibitor selectivity
    Davis, Mindy I.
    Hunt, Jeremy P.
    Herrgard, Sanna
    Ciceri, Pietro
    Wodicka, Lisa M.
    Pallares, Gabriel
    Hocker, Michael
    Treiber, Daniel K.
    Zarrinkar, Patrick P.
    [J]. NATURE BIOTECHNOLOGY, 2011, 29 (11) : 1046 - U124
  • [8] Unsupported off-label chemotherapy in metastatic colon cancer
    de Souza, Jonas A.
    Polite, Blase
    Perkins, Monica
    Meropol, Neal J.
    Ratain, Mark J.
    Newcomer, Lee N.
    Alexander, G. Caleb
    [J]. BMC HEALTH SERVICES RESEARCH, 2012, 12
  • [9] Dietrich S, 2012, NEW ENGL J MED, V366, P2038, DOI 10.1056/NEJMc1202124
  • [10] The off-label use of targeted therapies in sarcomas: the OUTC'S program
    Eberst, Lauriane
    Cropet, Claire
    Le Cesne, Axel
    Pautier, Patricia
    Penel, Nicolas
    Adenis, Antoine
    Chevreau, Christine
    Bay, Jacques-Olivier
    Collard, Olivier
    Cupissol, Didier
    Duffaud, Florence
    Gentet, Jean-Claude
    Piperno-Neumann, Sophie
    Marec-Berard, Perrine
    Bompas, Emmanuelle
    Thyss, Antoine
    Chaigneau, Loic
    Cassier, Philippe
    Bertucci, Francois
    Blay, Jean-Yves
    Ray-Coquard, Isabelle
    [J]. BMC CANCER, 2014, 14
123